Patent US4904649A successfully refreshed from Google Patents.
US4904649A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and solution for treating glaucoma
Assignee: New England Medical Center Hospitals Inc
•
Filing: 1987-03-27
•
Granted: 1990-02-27
•
Expires: 2007-03-27
Abstract
Abstract A method for treating glaucoma consisting of exposing the eye to a corticosteroid and a beta adrenergic agent to the eye which acts to decrease ocular pressure. Useful adrenergic agents include beta agonists antagonists, including, for example, epinephrine, dipivalyl epinephrine, betaxolol, levobunolol, and timolol. Useful steroids, which are preferably applied topically, include dexamethasone, prednisolone, cortisone, and triamcinolone. The beta adrenergic agent is administered at a concentration between about 10% and 20% of the concentration that the agent is administered in its normal use. The corticosteroid is administered at a concentration between 5% and 10% of the concentration that the corticosteroid is administered in its normal use.
Inventors
- 👤 Bernard Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 21:41
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
204 words
A method for treating elevated intraocular pressure in a mammalian eye comprising: administering to the eye a therapeutically effective amount of a corticosteroid and a beta adrenergic agent, said corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.005 to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8%, triamcinolone having a concentration of 0.0005 to 0.01% and their physiologically acceptable salts; said beta adrenergic agent selected from the group consisting of epinephrine having a concentration from 0.05 to 0.1%, cartelol having a concentration ranging fron 0.1 to 0.4%, dipivalyl epinephrine having a concentration from 0.01 to 0.02%, betaxolol having a concentration from 0.05 to 0.1%, timolol having a concentration from 0.025 to 0.1%, levobunolol having a concentration from 0.05 to 0.1% and their physiologically acceptable salts; the concentration of said corticosteroid and said beta adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said beta adrenergic agent.
Claim 2
Independent Claim
204 words
A method for treating elevated intraocular pressure in a mammalian eye comprising: administering to the eye a therapeutically effective amount of a corticosteroid and a beta adrenergic agent, said corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.005 to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8%, triamcinolone having a concentration of 0.0005 to 0.01% and their physiologically acceptable salts; said beta adrenergic agent selected from the group consisting of epinephrine having a concentration from 0.05 to 0.1%, cartelol having a concentration ranging fron 0.1 to 0.4%, dipivalyl epinephrine having a concentration from 0.01 to 0.02%, betaxolol having a concentration from 0.05 to 0.1%, timolol having a concentration from 0.025 to 0.1%, levobunolol having a concentration from 0.05 to 0.1% and their physiologically acceptable salts; the concentration of said corticosteroid and said beta adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said beta adrenergic agent.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein said corticosteroid and said beta adrenergic agent are applied in combination.
Claim 4
Dependent Claim
17 words
The method of claim 1 wherein said corticosteroid and said beta adrenergic agent are applied in sequence.
Claim 5
Dependent Claim
11 words
The method of claim 3 wherein the corticosteroid is administered systemically.
Claim 6
Dependent Claim
188 words
A solution for treating elevated intraocular pressure in a mammalian eye comprising: a corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.005 to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8% triamcinolone having a concentration of 0.0005 to 0.01% and their physiologically acceptable salts; a beta adrenergic agent selected from the group consisting of epinephrine having a concentration from 0.05 to 0.1%, cartelol having a concentration ranging from 0.1 to 0.4% dipivalyl epinephrine having a concentration from 0.01 to 0.02%, betaxolol having a concentration from 0.05 to 0.1%, timolol having a concentration from 0.025 to 0.1%, levobunolol having a concentration from 0.05 to 0.1% and their physiologically acceptable salts; the concentration of said corticosteroid and said beta adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said beta adrenergic agent.
Claim 7
Dependent Claim
188 words
A solution for treating elevated intraocular pressure in a mammalian eye comprising: a corticosteroid selected from the group consisting of dexamethasone having a concentration from 0.0005 to 0.01%, prednisolone having a concentration from 0.005 to 0.1%, hydrocortisone having a concentration from 0.0025 to 0.05%, cortisone having a concentration from 0.0125 to 0.25%, fluorometholone having a concentration from 0.0005 to 0.01%, betamethasone having a concentration from 0.0005 to 0.01%, methyl prednisolone having a concentration from 0.04 to 0.8% triamcinolone having a concentration of 0.0005 to 0.01% and their physiologically acceptable salts; a beta adrenergic agent selected from the group consisting of epinephrine having a concentration from 0.05 to 0.1%, cartelol having a concentration ranging from 0.1 to 0.4% dipivalyl epinephrine having a concentration from 0.01 to 0.02%, betaxolol having a concentration from 0.05 to 0.1%, timolol having a concentration from 0.025 to 0.1%, levobunolol having a concentration from 0.05 to 0.1% and their physiologically acceptable salts; the concentration of said corticosteroid and said beta adrenergic agent being selected to produce a prolonged decrease in intraocular pressure while minimizing undesirable side effects of said corticosteroid and said beta adrenergic agent.
References Cited (Backward Citations)
GB755156A
Cited
US2801202A
Cited
US3320125A
Cited
US4271143A
Cited
US4255415A
Cited
US4474751A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-26 | 1993-08-28 | 1994-02-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-26 | 1997-08-28 | 1998-02-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-26 | 2001-08-28 | 2002-02-27 | $7700.00 | Window Closed / Lapsed |